Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.99 Billion KRW | -6.96% |
| 2022 | 4.55 Billion KRW | -58.67% |
| 2021 | 11.45 Billion KRW | 14.04% |
| 2020 | 8.82 Billion KRW | -49.53% |
| 2019 | 20.18 Billion KRW | 88.93% |
| 2018 | 7.46 Billion KRW | 51.87% |
| 2017 | 5.7 Billion KRW | 199.2% |
| 2016 | 2.52 Billion KRW | 224.84% |
| 2015 | -1.82 Billion KRW | -156.27% |
| 2014 | -9.5 Billion KRW | 132.88% |
| 2013 | -17.25 Billion KRW | -4961.73% |
| 2012 | 153.13 Million KRW | 105.0% |
| 2011 | -8.39 Billion KRW | -157.46% |
| 2010 | 8.14 Billion KRW | 9.63% |
| 2009 | 7.43 Billion KRW | 64.24% |
| 2008 | 6.68 Billion KRW | 145.94% |
| 2007 | 1.83 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 119 Million KRW | 121.98% |
| 2024 Q2 | -3.05 Billion KRW | -474.17% |
| 2024 Q3 | 430 Million KRW | 114.07% |
| 2023 Q3 | 17.54 Billion KRW | -35.49% |
| 2023 Q4 | -3.55 Billion KRW | -120.28% |
| 2023 Q2 | 27.2 Billion KRW | 4454.02% |
| 2023 Q1 | -624.8 Million KRW | -138.74% |
| 2023 FY | - KRW | -6.96% |
| 2022 Q1 | 283.62 Million KRW | -78.08% |
| 2022 Q3 | 1.43 Billion KRW | -29.66% |
| 2022 Q4 | 1.61 Billion KRW | 12.66% |
| 2022 FY | - KRW | -58.67% |
| 2022 Q2 | 2.03 Billion KRW | 617.62% |
| 2021 Q1 | 6.36 Billion KRW | 250.7% |
| 2021 Q3 | 2.78 Billion KRW | 10.28% |
| 2021 Q4 | 1.29 Billion KRW | -53.57% |
| 2021 Q2 | 2.52 Billion KRW | -60.31% |
| 2021 FY | - KRW | 14.04% |
| 2020 FY | - KRW | -49.53% |
| 2020 Q2 | 3.21 Billion KRW | -17.45% |
| 2020 Q3 | 2.44 Billion KRW | -23.94% |
| 2020 Q1 | 3.89 Billion KRW | -6.04% |
| 2020 Q4 | 1.81 Billion KRW | -25.81% |
| 2019 FY | - KRW | 88.93% |
| 2019 Q2 | 8.26 Billion KRW | 108.96% |
| 2019 Q3 | 6.17 Billion KRW | -25.22% |
| 2019 Q4 | 4.14 Billion KRW | -32.86% |
| 2019 Q1 | 3.95 Billion KRW | -39.1% |
| 2018 Q2 | 2.06 Billion KRW | 169.66% |
| 2018 FY | - KRW | 51.87% |
| 2018 Q4 | 6.49 Billion KRW | 149.16% |
| 2018 Q3 | 2.6 Billion KRW | 26.12% |
| 2018 Q1 | 766.39 Million KRW | -84.47% |
| 2017 Q1 | -271.58 Million KRW | 27.19% |
| 2017 Q4 | 4.93 Billion KRW | 107.27% |
| 2017 FY | - KRW | 199.2% |
| 2017 Q2 | 812.5 Million KRW | 399.17% |
| 2017 Q3 | 2.38 Billion KRW | 193.08% |
| 2016 Q4 | -373.01 Million KRW | 20.13% |
| 2016 FY | - KRW | 224.84% |
| 2016 Q1 | 2.26 Billion KRW | 222.71% |
| 2016 Q2 | 1.2 Billion KRW | -46.76% |
| 2016 Q3 | -467.04 Million KRW | -138.78% |
| 2015 Q4 | -1.84 Billion KRW | 1.38% |
| 2015 Q2 | 853.81 Million KRW | 13.06% |
| 2015 Q3 | -1.86 Billion KRW | -318.92% |
| 2015 Q1 | 755.17 Million KRW | -31.38% |
| 2015 FY | - KRW | -156.27% |
| 2014 Q3 | 446.13 Million KRW | -48.57% |
| 2014 FY | - KRW | 132.88% |
| 2014 Q1 | 1.32 Billion KRW | 128.48% |
| 2014 Q4 | 1.1 Billion KRW | 146.68% |
| 2014 Q2 | 867.45 Million KRW | -34.5% |
| 2013 FY | - KRW | -4961.73% |
| 2013 Q4 | -4.65 Billion KRW | -4.81% |
| 2013 Q3 | -4.43 Billion KRW | -228.35% |
| 2013 Q2 | -1.35 Billion KRW | -44.96% |
| 2013 Q1 | -932.13 Million KRW | 15.22% |
| 2012 Q2 | -1.16 Billion KRW | -558.08% |
| 2012 FY | - KRW | 105.0% |
| 2012 Q4 | -1.09 Billion KRW | -166.5% |
| 2012 Q3 | 1.65 Billion KRW | 242.44% |
| 2012 Q1 | 253.35 Million KRW | 0.0% |
| 2011 Q2 | -5.07 Billion KRW | -383.5% |
| 2011 FY | - KRW | -157.46% |
| 2011 Q1 | 1.78 Billion KRW | -44.4% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 Q3 | -1.34 Billion KRW | 73.5% |
| 2010 Q1 | 1.41 Billion KRW | -39.39% |
| 2010 FY | - KRW | 9.63% |
| 2010 Q4 | 3.21 Billion KRW | 97.69% |
| 2010 Q3 | 1.62 Billion KRW | -13.61% |
| 2010 Q2 | 1.88 Billion KRW | 33.36% |
| 2009 Q2 | 2.02 Billion KRW | 38.65% |
| 2009 Q1 | 1.46 Billion KRW | -20.94% |
| 2009 Q3 | 1.61 Billion KRW | -20.46% |
| 2009 Q4 | 2.33 Billion KRW | 44.72% |
| 2009 FY | - KRW | 64.24% |
| 2008 Q3 | 1.57 Billion KRW | 184.93% |
| 2008 Q4 | 1.84 Billion KRW | 17.09% |
| 2008 FY | - KRW | 145.94% |
| 2008 Q1 | 543.48 Million KRW | -13.46% |
| 2008 Q2 | 553.63 Million KRW | 1.87% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q2 | 845.65 Million KRW | 270.35% |
| 2007 Q3 | 861.24 Million KRW | 1.84% |
| 2007 Q1 | -496.42 Million KRW | 0.0% |
| 2007 Q4 | 628.03 Million KRW | -27.08% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2.717% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 96.47% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 107.793% |
| HANDOK Inc. | 35.06 Billion KRW | 85.769% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 581.424% |
| Yuhan Corporation | 127.43 Billion KRW | 96.084% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 86.7% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 123.01% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 98.457% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 66.991% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -45.874% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -10.249% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 85.937% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2.717% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 127.016% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 23.87% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 110.124% |
| JW Holdings Corporation | 187.88 Billion KRW | 97.344% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 109.741% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 98.241% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.407% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 113.463% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 62.222% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 57.809% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 73.249% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -2.717% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 90.922% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 96.974% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.407% |
| Yuhan Corporation | 127.43 Billion KRW | 96.084% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 85.093% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 34.766% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 93.521% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.407% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 86.378% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 92.95% |
| CKD Bio Corp. | -1.63 Billion KRW | 406.072% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 89.978% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 84.674% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 86.443% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 113.463% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 91.988% |
| Boryung Corporation | 114.28 Billion KRW | 95.634% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 116.325% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 66.991% |
| JW Lifescience Corporation | 50.82 Billion KRW | 90.182% |